| William J Dunn, MD | |
|
529 Health Blvd, Daytona Beach, FL 32114-1493 | |
| (800) 255-7188 | |
| (386) 239-9758 |
| Full Name | William J Dunn |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 44 Years |
| Location | 529 Health Blvd, Daytona Beach, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225038441 | NPI | - | NPPES |
| 053678400 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0107X | Ophthalmology - Retina Specialist | ME59918 (Florida) | Secondary |
| 207W00000X | Ophthalmology | ME0059918 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ophthalmic Partners Of Florida Pa | 5698688182 | 5 |
News Archive
Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.
Officials say they are expecting glitches, but most do not expect the crippling technical problems that afflicted last year's open enrollment period.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.
Onyx Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.
› Verified 1 days ago
| Entity Name | Ophthalmic Partners Of Florida Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740387968 PECOS PAC ID: 5698688182 Enrollment ID: O20031209000689 |
News Archive
Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.
Officials say they are expecting glitches, but most do not expect the crippling technical problems that afflicted last year's open enrollment period.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.
Onyx Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William J Dunn, MD 3824 Oakwater Cir, Orlando, FL 32806-6263 Ph: (800) 255-7188 | William J Dunn, MD 529 Health Blvd, Daytona Beach, FL 32114-1493 Ph: (800) 255-7188 |
News Archive
Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.
Officials say they are expecting glitches, but most do not expect the crippling technical problems that afflicted last year's open enrollment period.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.
Onyx Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.
› Verified 1 days ago
Dr. Annemarie Etienne, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 350 N Clyde Morris Blvd, Daytona Beach, FL 32114 Phone: 386-676-7103 Fax: 386-676-7186 | |
Nishita D Patel, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 517 N Clyde Morris Blvd, Daytona Beach, FL 32114 Phone: 386-425-0393 Fax: 386-253-3484 | |
Robert Runyan Young, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 505 Health Blvd, Daytona Beach, FL 32114 Phone: 386-255-5050 Fax: 386-255-5029 | |
Suzanne M. Demming, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 529 Health Blvd, Daytona Beach, FL 32114 Phone: 386-254-1951 Fax: 386-239-9758 | |
Asher Yerucham Neren, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 350 N Clyde Morris Blvd, Daytona Beach, FL 32114 Phone: 386-676-7103 Fax: 386-676-7186 | |
Karl Ellsworth Waite, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 529 Health Blvd, Daytona Beach, FL 32114 Phone: 800-255-7188 Fax: 386-239-9758 |